Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
TWST proposes sale of 26,137 shares of Common Stock via stock option exercise. The filing states the sale date as 06/15/2026 and lists Fidelity Brokerage Services LLC as the broker-dealer. The filing also lists recent dispositions by Paula Green totaling 3,696 shares on 03/20/2026, 05/04/2026, 05/21/2026, and 06/08/2026 with cash amounts shown for each sale.
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 402 shares of common stock at an average price of $69.8442 per share. After this transaction, he directly holds 119,692 shares. According to the disclosure, the sale was mandated to cover tax withholding on vesting Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade.
Twist Bioscience Corp SVP of Human Resources Paula Green reported a small mandated share sale tied to tax withholding. She sold 884 shares of common stock at an average price of $69.8442 per share to cover taxes due on vesting Restricted Stock Units, under a required “sell to cover” election in the company’s equity incentive plans. After this non-discretionary transaction, she directly holds 120,705 shares.
Twist Bioscience Corp reported that Chief Executive Officer Emily M. Leproust sold 2,265 shares of common stock at $69.8442 per share. According to the disclosure, these shares were sold to cover tax withholding obligations related to vesting Restricted Stock Units under the company’s equity incentive plans, rather than as discretionary trades.
After this tax-related sale, Leproust directly holds 844,607 shares of common stock. She also holds employee stock options to purchase 64,950 shares of common stock at an exercise price of $67.85 per share, which are immediately exercisable and expire on August 31, 2030.
Twist Bioscience Corp's Chief Accounting Officer, Robert F. Werner, reported routine share movements in common stock. On June 8, 2026, he sold a total of 1,359 shares in two open-market transactions at prices of $69.07 and $69.8442 per share.
According to the disclosure, these sales were required to cover tax withholding obligations tied to vesting Restricted Stock Units under the company’s equity plans, and were not discretionary trades. Werner also made a bona fide gift of 500 shares to a charitable organization and continues to hold 47,954 shares directly.
TWST reported insider sales via Form 144 by Robert F. Werner. The filing lists four disposals of Common shares on ranging from $9,372.40 to $282,186.64, with share counts of 164, 4,961, 688, and 800. The transactions follow recent restricted stock vesting events on for compensation.
Company reports a Form 144 notice for proposed sales of Common Stock by an affiliate. The filing lists restricted stock vesting on 06/05/2026 and multiple dispositions by Dennis H. Cho during March–May 2026, including sales on 05/29/2026 of 14,205 shares at a reported aggregate value of $990,798.75.
The document records earlier sales of 354, 1,962, and 1,642 shares on 03/20/2026, 05/04/2026, and 05/21/2026 respectively, with aggregate values shown in the filing. The securities disposition is identified as compensation-related vesting and affiliate resale activity.
TWST reports proposed resale of 232 shares of common stock under a Rule 144 notice. The filing lists the securities as issued for Restricted Stock Vesting on 06/05/2026 and attributed to compensation.
The filing also discloses past sales by Robert F. Werner: 164 shares for $9,372.40 on 05/04/2026, 4,961 shares for $282,186.64 on 05/08/2026, 688 shares for $36,640.54 on 05/21/2026, and 800 shares for $49,987.20 on 05/26/2026.
TWST reported an insider sale filing under Rule 144 for Common Stock. The filing lists 884 shares of Common Stock to be sold on 06/05/2026 following a Restricted Stock Vesting entry. The filing also discloses three prior dispositions by Paula Green of 297, 1,116 and 1,399 shares on 03/20/2026, 05/04/2026 and 05/21/2026, respectively.
TWST director Emily M. Leproust reported multiple open-market dispositions of Common Stock. The filing lists planned sale of 2,265 shares in connection with restricted stock vesting on 06/05/2026 and a series of sales during March–May 2026, including transactions of $1,580,245.85 on 05/26/2026 and $1,633,407.46 on 05/27/2026.
The filings itemize individual sale dates and proceeds; post-transaction holdings and cash‑flow treatment are shown in the reported rows.